You are here

Kasabach-Merritt Fenomeni yönetiminde vinkristin başarıyla kullanımı

Successful use of vincristine in the management of Kasabach-Merritt Phenomenon

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
A 2-month old boy with Kaposiform Hemangioendothelioma of the lumbosacral region invading the retroperitoneum was admitted with Kasabach-Merritt Phenomenon. After corticosteroid and interferon treatments failed with progression of the disease to a life threatening condition, vincristine monotreatment granted a rapid rise in platelet counts, fibrinogen levels and a resolution in the enlargement of the lesion. The remission was maintained and no adverse effects were observed during the treatment. Vincristin therapy may be suggested instead of multidrugs as first line therapy in patients with KMP.
Abstract (Original Language): 
İki aylık erkek bebek, lumbosakral bölgede retroperitonu tutan Kaposiform Hemangioendothelioma ile, Kasabach Merrit penomeni (KMp) tanısı konarak hastaneye kabul edildi. Kortikosteroid ve interferon tedavileri hastalığın ilerlemesinde başarısız oldu. Vincristin mono tedavisi ile fibrinojen ve trombosit sayısı hızlı yükseldi, lezyon büyümesi geriledi. Remisyon sağlandı ve tedavi süresince yan etkiler gözlenmedi. Tedavisi kesildikten 6 ay sonra rölaps oluşmadı. KMp de çoklu ilaç tedavisi yerine ilk seçenek olarak vincristin tedavisi düşünülebilinir.
55-58

REFERENCES

References: 

1. Hall GW: Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001;112(4):851-862.
2. Kwok-Williams M, Perez Z, Squire R, Glaser A, Bew S, Taylor R. Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome. _2007;49(5):739-44.
3. Chung T, Hoffer FA, Burrows PE, et al. MR imaging ofhepatic hemangiomas ofinfancy and changes seen with interferon alpha-2a treatment. Pediatr Radiol 1996;26(5):341-348.
4. Akyuz C, Yaris N, Kutluk MT, et al. Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol 2001;18(1): 47-55.
5. Koerper MA, Addiego JE Jr, deLorimier AA, et al. Use ofaspirin and dipyridamole in children with platelet trapping syndromes. J Pediatr 1983;102(2):311-314.
6. Prost Y, Teillac D, Bodemer C, et al. Successful treatment of Kasabach -Merritt syndrome with pentoxifylline. J Am Acad Dermatol 1991;25(5 Pt
1):854-855.
7. Dresse MF, David M, Hume H, et al. Successful treatment of Kasabach -Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 1991;8(4):329-334.
8. Ezekowitz A, Mulliken J, Folkman J. Interferon alpha therapy ofhaemangiomas in newborns and infants. Br JHaematol 1991;79(Suppl 1):67-68.
9. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326(22):1456-1463.
10. Harper L, Michel JL, Enjolras O, Raynaud-MounetN, Riviere JP, Heigele T, De Napoli-Cocci S. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon. Eur J Pediatr Surg. 2006;16(5):369-72.
S.D.Ü. Tıp pak.
Derg
. 2012:19(2)/55-58
58
Canatan, vincristine and Kasabach-Merritt Phenomenon
11. Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, de Laat PC, Madern GC, Gonzalez F, Frangoul H, Le Moine P, Prose NS, Adams DM. Kasabach-Merritt phenomenon: a retrospective study oftreatment with vincristine. J Pediatr Hematol Oncol
2002;24(6):459-462.
12. Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review ofliterature. Cases J 2008;1(1):9.
13. Yesudian PD, Parslew R, Klafowski J, Gould D, Pizer B. Tufted angioma-associated Kasabach-Merritt syndrome treated with embolization and vincristine. Plast Reconstr Surg. 2008;121(2):692-3.
14. Thomson K, Pinnock R, Teague L, Johnson R, Manikkam N, Drake R. Vincristine for the treatment ofKasabach-Merritt syndrome: recentNew Zealand case experience. N Z Med J. 2007;120(1249):U2418.
15. Taki M, Ohi C, Yamashita A, Kobayashi M, Kobayashi N, Yoda T, Horiuchi T, Aikyou M, Horikoshi Y, Mimaya J. Successful treatment with vincristine ofan infant with intractable Kasabach-Merritt syndrome. PediatrInt. 2006;48(1):82-4.
16. Hoyoux C: Vincristine treatment for management of alarming hemangiomas in infancy. Rev Med Liege.2008;63(1):14-7.

Thank you for copying data from http://www.arastirmax.com